MedTrace Logo

Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin

NCT05654298 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-03-28

No results posted yet for this study

Summary

The involvement of calcitonin gene-related peptide (CGRP) in the cinnamaldehyde-induced dermal blood flow increase and in the mechanism of action of triptans will be investigated. The capsaicin-induced dermal blood flow will be incorporated as a positive control; histamine skin pricks as a negative control. Changes in dermal blood flow will be measured with laser speckle contrast imaging.

Conditions

Interventions

DRUG

Sumatriptan

Sumatriptan 100 mg

DRUG

Ubrogepant

Ubrogepant 100 mg

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2023-03-15
Completion
2023-03-15

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05654298 on ClinicalTrials.gov